PCM
GBT

Prelude Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Prelude Capital Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-125,029
Closed -$8.51M – 1938
2022
Q3 		$8.51M Buy
+125,029
New +$6.9M 0.31% 46
2020
Q4 		– Sell
-7,705
Closed -$425K – 2194
2020
Q3 		$425K Buy
7,705
+1,855
+32% +$118K 0.02% 476
2020
Q2 		$369K Buy
+5,850
New +$401K 0.02% 561
2020
Q1 		– Sell
-138
Closed -$11K – 2205
2019
Q4 		$11K Buy
138
+15
+12% +$889 ﹤0.01% 1694
2019
Q3 		$6K Sell
123
-18,033
-99% -$940K ﹤0.01% 1557
2019
Q2 		$955K Buy
18,156
+7,708
+74% +$443K 0.05% 353
2019
Q1 		$553K Buy
+10,448
New +$513K 0.03% 473
2018
Q4 		– Sell
-57,446
Closed -$2.18M – 2280
2018
Q3 		$2.18M Buy
57,446
+8,283
+17% +$367K 0.13% 170
2018
Q2 		$2.22M Buy
49,163
+20,784
+73% +$946K 0.14% 129
2018
Q1 		$1.37M Buy
28,379
+26,183
+1,192% +$1.46M 0.1% 205
2017
Q4 		$86K Sell
2,196
-5,397
-71% -$202K 0.01% 821
2017
Q3 		$236K Buy
7,593
+2,593
+52% +$72.9K 0.02% 589
2017
Q2 		$137K Buy
5,000
+800
+19% +$23.8K 0.01% 697
2017
Q1 		$155K Sell
4,200
-300
-7% -$7.56K 0.01% 648
2016
Q4 		$65K Sell
4,500
-1,700
-27% -$29.9K 0.01% 975
2016
Q3 		$143K Buy
+6,200
New +$118K 0.02% 680

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Prelude Capital Management's GBT Position: Q4 2022 in Review

Prelude Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 125,029 shares — an estimated $8.51M sold.

Prelude Capital Management first reported a position in GBT in Q3 2016 and held it in 16 quarters. The position peaked at $8.51M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Prelude Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Prelude Capital Management sold 125,029 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $8.51M.
  • Prelude Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q3 2016 and held it in 16 quarters.
  • Prelude Capital Management's Global Blood Therapeutics, Inc. position peaked at $8.51M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Prelude Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.